Wednesday, 03 September 2008

EU Programme to develop avian influenza vaccine

Archimedes Development Ltd, a subsidiary of Archimedes Pharma Ltd, the UK-based pan-European specialty pharmaceutical company, today announced it has received EU funding totalling €2.77 million, over three years, for a collaborative project to reduce the threat of an avian influenza pandemic by developing a vaccine against the avian influenza virus. The Nasal Pandemic Influenza Vaccine (NASPANVAC) project is funded by the European Union under the FP7 scheme.